Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SRPT
SAREPTA THERAPEUTICS, INC.
NASDAQ
$20.86
▼ DOWN 3.38% (-0.73)

KEY STATISTICS

Market Cap$2.20 B
52w High$25.32
52w Low$14.68
Dividend Yield—
Frequency—
P/E-34.77
Volume3.61M
Shares Out.105.58M

COMPANY

LEADERSHIP

Michael E. Severino
CHIEF EXECUTIVE
Michael E. Severino

COMPENSATION 2026

Salary$1,171,425
Stock Awards$6,000,005
Incentive Plan Pay$649,000
All Other Comp.$20,236
Total$7,840,666

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 4, 1997
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
835

PRICE TARGET

Target High$35.00
Target Low$14.00
Target Median$25.00
Target Consensus$25.11

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$354.38M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2012-07-12Reverse1:6

PRICE

$20.86 ▼ DOWN 3.38% (−$0.73)
OVERLAYS
$21.00$21.50$22.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM20.86

About Sarepta Therapeutics, Inc.

https://www.sarepta.com ↗

Sarepta Therapeutics develops RNA-targeted therapies and gene treatments for rare diseases, notably Duchenne muscular dystrophy, with products like EXONDYS 51 and VYONDYS 53, and collaborates with various institutions.

INDUSTRY

Biotechnology

A PRODUCT SAREPTA THERAPEUTICS, INC. IS KNOWN FOR

ELEVIDYS (delandistrogene moxeparvovec-rokl)
ELEVIDYS (delandistrogene moxeparvovec-rokl)

ELEVIDYS is a one-time gene therapy for Duchenne muscular dystrophy, approved for patients aged 4 and older, and is Sarepta's leading growth driver projected to exceed $1.5 billion in sales by 2025.

COMPETITORS

COMPETITOR
CAPR COMPARE
PFE COMPARE
PTCT COMPARE
RGNX COMPARE
SLDB COMPARE

Revenue by Products

IconPRODUCTQ1-2021Q2-2021Q3-2021
E X O N D Y S Fifty One$107.19M $112.46M ▲$115.6M ▲
A M O N D Y S Fourty Five$193K $6.94M ▲$26.66M ▲
V Y O N D Y S Fifty Three$17.55M $22.44M ▲$24.66M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$209.13M $32.76M ▼$188.79M ▲$198.6M ▲
NonUS— — $39.76M $31.96M ▼
Rest Of World$29.41M — — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
234
LISTED HERE
26
RANKED BY POSITION SIZE
XSMC.TO
0.11% · 6.4M
FBT
3.45% · 4.8M
XBI
0.86% · 4.7M
VTI
0.00% · 3.2M
PBE
2.92% · 552.2K
SCHA
0.05% · 504.6K
FESM
0.13% · 389.0K
BSVO
0.32% · 377.5K
DFMC
0.07% · 274.0K
MNVT
5.25% · 191.4K
LABU
0.59% · 172.4K
EES
0.45% · 165.1K
AVSC
0.09% · 132.6K
SBIO
1.12% · 130.1K
BBP
1.73% · 95.6K
XRSG.L
0.07% · 95.2K
HAPS
0.96% · 79.2K
GNOM
1.61% · 71.2K
JMEE
0.04% · 50.8K
TQSM.TO
0.13% · 46.9K
GSSC
0.09% · 46.9K
BIOT.L
2.91% · 32.7K
AFTY
0.35% · 14.0K
TILT
0.01% · 13.9K
ZSML.TO
0.12% · 10.2K
SAGP
0.26% · 9.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
575
TOP 12 OF 575 · RANKED BY POSITION SIZE
Tudor Investment Corp Et Al
68.8M sh · $63.35M
Blackrock, Inc.
19.0M sh · $341.34M
Vanguard Group Inc
11.8M sh · $254.17M
Blackrock Inc.
10.3M sh · $1.63B
State Street Corp
8.9M sh · $160.22M
Aqr Capital Management LLC
7.8M sh · $167.78M
Two Sigma Investments, LP
4.6M sh · $82.64M
First Trust Advisors LP
4.4M sh · $78.46M
Ra Capital Management, L.P.
3.9M sh · $84.92M
Erste Asset Management Gmbh
3.0M sh · $61.29M
Geode Capital Management, LLC
2.8M sh · $49.82M
Renaissance Technologies LLC
2.7M sh · $51.07M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Josh Gottheimer
Josh Gottheimer
Purchase
2023-07-14
 Daniel Goldman
Daniel Goldman
Sale
2023-04-10
 Gilbert Cisneros
Gilbert Cisneros
Purchase
2020-09-14

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
SEVERINO MICHAEL
Purchase · 2.2M shares
2026-07-28
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
SEVERINO MICHAEL
Purchase · 756.1K shares
2026-07-28
★
SEVERINO MICHAEL
— · —
2026-07-28
★
DIRECTOR
Boor Kathryn Jean
Purchase · 16.9K shares
2026-06-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 5
NEUTRAL 2
SELL 2
UNDERPERFORM 1
OVERWEIGHT 1
BUY 1
EQUAL WEIGHT 1
MARKET PERFORM 1
14 GRADES IN THE LAST 12 MONTHS
Piper Sandler NEUTRAL Wolfe Research OUTPERFORM HC Wainwright & Co. SELL Needham UNDERPERFORM Citigroup SELL Oppenheimer OUTPERFORM Mizuho OUTPERFORM Wells Fargo OVERWEIGHT

SECTORS PEERS

PEERPRICE
IBRX$8.05COMPARE
COGT$34.67COMPARE
ADPT$25.19COMPARE
DNLI$24.00COMPARE
RCUS$29.21COMPARE
BEAM$29.32COMPARE
MLYS$25.60COMPARE
AGIO$33.32COMPARE